Tactile Systems Technology, Inc. announced that it is acquiring LymphaTech for an upfront cash payment at closing of $6.8 million, plus potential additional consideration that is contingent upon the achievement of future milestones.
Founded in 2014, LymphaTech is a privately held medical technology company pioneering a digital, three-dimensional full body measurement and monitoring platform designed specifically for lymphedema.
Tactile Systems Technology is a medical technology company focused on developing medical devices for the treatment of underserved chronic diseases at home. The company develops and markets at-home therapies for people suffering from underserved, chronic conditions, including lymphedema, lipedema, chronic venous insufficiency and chronic inflammatory lung disease.
The acquisition will expand Tactile Medical’s lymphedema portfolio with new solutions that enable more accurate and efficient disease identification and progression, while broadening Tactile’s research and development capabilities and strengthening its market leadership position in conditions associated with lymphatic dysfunction. In connection with the transaction, LymphaTech co-founders Mike Weiler, PhD, and Nate Frank, MBA, have joined Tactile Medical to drive commercial adoption of the LymphaTech platform and support ongoing research activities.
According to data captured in the LevinPro HC database, this marks the 18th Medical Device transaction of 2026. There were 86 Medical Device deals announced during 2025, 87 announced in 2024 and 112 announced during 2023.
